| A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control Z Sun, Z Ren, K Yang, Z Liu, S Cao, S Deng, L Xu, Y Liang, J Guo, Y Bian, ... Nature communications 10 (1), 3874, 2019 | 169 | 2019 |
| Lactate increases stemness of CD8+ T cells to augment anti-tumor immunity Q Feng, Z Liu, X Yu, T Huang, J Chen, J Wang, J Wilhelm, S Li, J Song, ... Nature communications 13 (1), 4981, 2022 | 139 | 2022 |
| Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2 Y Yu, R Gong, Y Mu, Y Chen, C Zhu, Z Sun, M Chen, Y Liu, Y Zhu, J Wu The Journal of Immunology 187 (9), 4844-4860, 2011 | 99 | 2011 |
| Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance Y Liang, H Tang, J Guo, X Qiu, Z Yang, Z Ren, Z Sun, Y Bian, L Xu, H Xu, ... Nature communications 9 (1), 4586, 2018 | 81 | 2018 |
| Clearing persistent extracellular antigen of hepatitis B virus: an immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination D Zhu, L Liu, D Yang, S Fu, Y Bian, Z Sun, J He, L Su, L Zhang, H Peng, ... The Journal of Immunology 196 (7), 3079-3087, 2016 | 76 | 2016 |
| A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy EJ Hsu, X Cao, B Moon, J Bae, Z Sun, Z Liu, YX Fu Nature communications 12 (1), 2768, 2021 | 74 | 2021 |
| Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice Y Bian, Z Zhang, Z Sun, J Zhao, D Zhu, Y Wang, S Fu, J Guo, L Liu, L Su, ... Hepatology 66 (4), 1067-1082, 2017 | 67 | 2017 |
| Tumor‐targeted inhibition of monocarboxylate transporter 1 improves T‐cell immunotherapy of solid tumors T Huang, Q Feng, Z Wang, W Li, Z Sun, J Wilhelm, G Huang, T Vo, ... Advanced healthcare materials 10 (4), 2000549, 2021 | 61 | 2021 |
| Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window X Wang, J Wilhelm, W Li, S Li, Z Wang, G Huang, J Wang, H Tang, ... Nature communications 11 (1), 5828, 2020 | 52 | 2020 |
| Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity Z Ren, A Zhang, Z Sun, Y Liang, J Ye, J Qiao, B Li, YX Fu The Journal of clinical investigation 132 (3), 2022 | 51 | 2022 |
| CTLA-4 limits anti-CD20–mediated tumor regression Z Ren, J Guo, J Liao, Y Luan, Z Liu, Z Sun, X Liu, Y Liang, H Peng, YX Fu Clinical Cancer Research 23 (1), 193-203, 2017 | 49 | 2017 |
| Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells L Liu, J Chen, J Bae, H Li, Z Sun, C Moore, E Hsu, C Han, J Qiao, YX Fu Nature biomedical engineering 5 (11), 1261-1273, 2021 | 43 | 2021 |
| Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3–CD8+ T cells S Deng, Z Sun, J Qiao, Y Liang, L Liu, C Dong, A Shen, Y Wang, H Tang, ... JCI insight 5 (7), 2020 | 42 | 2020 |
| Hepatitis B virus e antigen activates the suppressor of cytokine signaling 2 to repress interferon action Y Yu, P Wan, Y Cao, W Zhang, J Chen, L Tan, Y Wang, Z Sun, Q Zhang, ... Scientific reports 7 (1), 1729, 2017 | 38 | 2017 |
| IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer J Bae, L Liu, C Moore, E Hsu, A Zhang, Z Ren, Z Sun, X Wang, J Zhu, ... Nature cell biology 24 (12), 1754-1765, 2022 | 29 | 2022 |
| Targeting tumor cells with antibodies enhances anti-tumor immunity Z Sun, YX Fu, H Peng Biophysics Reports 4, 243-253, 2018 | 21 | 2018 |
| Converting lymphoma cells into potent antigen-presenting cells for interferon-induced tumor regression J Liao, Y Luan, Z Ren, X Liu, D Xue, H Xu, Z Sun, K Yang, H Peng, YX Fu Cancer immunology research 5 (7), 560-570, 2017 | 13 | 2017 |
| T cell-derived lymphotoxin is essential for the anti-herpes simplex virus 1 humoral immune response K Yang, Y Liang, Z Sun, D Xue, H Xu, M Zhu, YX Fu, H Peng Journal of virology 92 (14), 10.1128/jvi. 00428-18, 2018 | 7 | 2018 |
| T cell-derived lymphotoxin limits Th1 response during HSV-1 infection K Yang, Y Liang, Z Sun, L Liu, J Liao, H Xu, M Zhu, YX Fu, H Peng Scientific reports 8 (1), 17727, 2018 | 6 | 2018 |
| STING licensing of type I dendritic cells potentiates antitumor immunity J Wang, S Li, M Wang, X Wang, S Chen, Z Sun, X Ren, G Huang, ... Science Immunology 9 (92), eadj3945, 2024 | 5 | 2024 |
